OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 126 filers reported holding OCULAR THERAPEUTIX INC in Q1 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,212 | -72.4% | 20,768 | -54.6% | 0.00% | -70.0% |
| Q2 2023 | $235,900 | -2.1% | 45,717 | 0.0% | 0.01% | -16.7% |
| Q1 2023 | $240,929 | -91.1% | 45,717 | -95.3% | 0.01% | -90.8% |
| Q4 2022 | $2,712,327 | -56.6% | 965,241 | -35.9% | 0.13% | -59.4% |
| Q3 2022 | $6,252,000 | +6.1% | 1,506,456 | +2.8% | 0.32% | +6.6% |
| Q2 2022 | $5,892,000 | -7.9% | 1,465,702 | +13.5% | 0.30% | +24.2% |
| Q1 2022 | $6,395,000 | -13.3% | 1,291,905 | +22.1% | 0.24% | -10.3% |
| Q4 2021 | $7,372,000 | -13.2% | 1,057,727 | +24.5% | 0.27% | -11.7% |
| Q3 2021 | $8,496,000 | -51.0% | 849,600 | -30.6% | 0.31% | -51.3% |
| Q2 2021 | $17,349,000 | -18.3% | 1,223,500 | -5.5% | 0.63% | -17.6% |
| Q1 2021 | $21,248,000 | -13.8% | 1,294,850 | +8.7% | 0.77% | -6.2% |
| Q4 2020 | $24,648,000 | – | 1,190,703 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,932,607 | $40,643,000 | 15.56% |
| Lamond Capital Partners LLC | 711,533 | $14,964,000 | 15.19% |
| Polaris Venture Management Co. V, L.L.C. | 1,230,009 | $25,867,000 | 11.54% |
| NOTTINGHAM ADVISORS, INC. | 171,985 | $3,617,000 | 0.60% |
| Portolan Capital Management | 122,518 | $2,577,000 | 0.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 160,000 | $3,365,000 | 0.33% |
| Rotella Capital Management, Inc. | 18,461 | $388,000 | 0.32% |
| Monashee Investment Management LLC | 28,834 | $606,000 | 0.29% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 335,498 | $7,056,000 | 0.24% |
| BAILARD, INC. | 55,000 | $1,157,000 | 0.18% |